Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.32 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19909114 | 0.94 | MAPK14 (0.39) | MAPK14CSNK1A1CSNK1DFLT3GRM5 | |
| SCHEMBL19909507 | 0.92 | MAPK14 (0.42) | MAPK14CSNK1A1CSNK1DFLT3BRAF | |
| SCHEMBL19908927 | 0.91 | AURKA (0.41) | MAPK14CSNK1A1CSNK1DMAP4K4GRM5 | |
| SCHEMBL19908959 | 0.90 | GRM5 (0.39) | MAPK14CSNK1A1CSNK1DFLT3BRAF | |
| SCHEMBL19908921 | 0.90 | MKNK1 (0.40) | MAPK14CSNK1A1CSNK1DFLT3AURKA | |
| SCHEMBL19909119 | 0.90 | FLT3 (0.37) | MAPK14CSNK1A1CSNK1DFLT3BRAF | |
| SCHEMBL21414200 | 0.89 | MAP4K4 (0.35) | MAP4K4 | |
| SCHEMBL19909067 | 0.89 | MAPKAPK2 (0.39) | MAPK14CSNK1A1CSNK1DFLT3GRM5 | |
| SCHEMBL19908950 | 0.88 | CSNK1A1 (0.41) | MAPK14CSNK1A1CSNK1DFLT3BRAF | |
| SCHEMBL19909109 | 0.87 | RXRA (0.39) | MAPK14CSNK1A1CSNK1DFLT3BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11588114-B2 | Organic molecules for use in optoelectronic devices | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-02-21 | — | — | US | disclosed |
| US-20200212316-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2020-07-02 | — | — | US | disclosed |
| US-10665792-B2 | Organic molecules for use in optoelectronic devices | CYNORA GMBH (DE) | 2020-05-26 | — | — | US | disclosed |
| US-20180062085-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-03-01 | — | — | US | disclosed |
| EP-3287451-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2018-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200212316-A1 | ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICES | OR10J3, OPRM1, OR51E2 | MAPK14 2544/4885CSNK1A1 4231/4885CSNK1D 3662/4885 |
| US-10665792-B2 | Organic molecules for use in optoelectronic devices | OR10J3, CFD, AOX1 | MAPK14 2787/4885CSNK1A1 2962/4885CSNK1D 1514/4885 |
| US-11588114-B2 | Organic molecules for use in optoelectronic devices | OR10J3, OPRM1, OR51E2 | MAPK14 2544/4885CSNK1A1 4231/4885CSNK1D 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.